-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Text | pick up shells
On July 21, Watson Biologics registered a phase III clinical trial of mRNA vaccine ARCoVaX (ARCoV) on the China Clinical Trial Network, which is the first phase III clinical trial of a domestic mRNA vaccine
The study will recruit 2,000 subjects in China, 500 with placebo, and 1,500 in the 15ug/0.
ARCoVaX was originally developed by Abbio.
Abbio is mainly responsible for the pre-clinical research of mRNA vaccines, and is responsible for the preparation of clinical application samples, clinical phase I and clinical phase II samples, and technology transfer
ARCoVaX is encapsulated by lipid nanoparticles (LNPs) and targets the RBD region of the SARS-CoV-2 spike protein
The vaccine was launched in a phase III clinical study abroad in May this year, and 28,000 subjects are planned to be recruited